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Introduction: The demonstration of anaplastic lymphoma kinase 
(ALK) positivity in non–small-cell lung cancer (NSCLC) has been 
hindered by the technical complexity and interpretative challenges of 
fluorescence in situ hybridization methods for detection of ALK gene 
rearrangement and by the inadequate sensitivity of existing immu-
nohistochemistry (IHC) methods for ALK protein detection. In this 
study, we sought to increase the sensitivity of ALK IHC detection 
and to develop a brightfield assay for concurrent detection of ALK 
protein expression and ALK gene rearrangement.
Methods: We developed a horseradish peroxidase–based IHC 
detection system using the novel, nonendogenous hapten 3-hydroxy-
2-quinoxaline (HQ) and tyramide. We also developed a dual gene 
protein ALK assay combining a brightfield break-apart in situ 
hybridization ALK assay with another sensitive IHC method using 
the novel, nonendogenous hapten 5-nitro-3-pyrazole. We exam-
ined the sensitivity and accuracy of these methods using surgically 
resected NSCLC cases examined with ALK fluorescence in situ 
hybridization.
Results: The new HQ-tyramide IHC detection system offered readily 
interpretable staining with substantially greater sensitivity than con-
ventional ALK IHC, and produced heterogeneous and homogeneous 
patterns of ALK protein staining among ALK-positive NSCLC surgi-
cal cases. The new 5-nitro-3-pyrazole–based IHC detection system 
was similar in ALK detection sensitivity to the HQ-tyramide IHC sys-
tem and was compatible with the brightfield in situ hybridization assay.
Conclusion: The new HQ-tyramide IHC reagent system allows more 
sensitive assessment of ALK protein status in NSCLC cases. The new 
ALK gene-protein assay allows the concurrent visualization of ALK 
gene and ALK protein status in single cells, allowing more accurate 
ALK status determination even in heterogeneous specimens.
Key Words: ALK, Brightfield, Immunohistochemistry, In situ 
hybridization, Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 1019-1031)
The implementation of personalized health care in cancer relies on the identification and characterization of cancer 
biomarkers and the availability of accurate detection systems 
and therapies for those biomarkers. For example, the human 
epidermal growth factor receptor 2 gene (HER2) and protein 
are well-established biomarkers for identifying those breast1 
and gastric cancer2 patients who are most likely to respond to 
trastuzumab therapy.
Anaplastic lymphoma kinase (ALK), a tyrosine kinase, 
is a more recently characterized cancer biomarker3; in non–
small-cell lung cancer (NSCLC), the presence of oncogenic 
ALK gene rearrangement leading to fusion of the ALK gene 
with any of several other specific genes is linked both to ALK 
protein overexpression and a dramatic therapeutic response 
to specific ALK inhibitors4 such as crizotinib (Pfizer, Inc., 
New York, NY), which has been approved for use in ALK-
positive, locally advanced or metastatic NSCLC.5 To identify 
NSCLC patients with ALK gene rearrangement in clinical tri-
als, researchers have used a break-apart fluorescence in situ 
hybridization (FISH) assay.5 However, the ALK FISH assay 
is fraught with technical challenges, including FISH signal 
instability and scoring difficulties.6–8
An alternative method for determining ALK diagnostic 
status in NSCLC is to identify ALK protein overexpression 
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using immunohistochemical (IHC) methods. However, the 
sensitive and reproducible detection of ALK by these methods 
presents a significant challenge because the differential expres-
sion of ALK protein occurs at a low level.6 Although a multiplex 
reverse transcription–polymerase chain reaction (RT-PCR)–
based assay can sensitively detect certain ALK fusion-gene vari-
ants,7,9 reproducible RT-PCR results are technically difficult to 
obtain in formalin-fixed, paraffin-embedded (FFPE) tissue sec-
tions.6,10 The various advantages and disadvantages of current 
ALK testing methodologies have led the Japanese Lung Cancer 
Society to recommend that multiple ALK tests should be used 
when an NSCLC patient is evaluated for anti-ALK therapy.11
The present report describes the successful development 
and evaluation of two new methodologies for the assessment 
of ALK status in FFPE NSCLC tissue. To improve IHC assay 
sensitivity, we incorporated the novel, nonendogenous hapten 
3-hydroxy-2-quinoxaline (HQ) and tyramide amplification 
into a diaminobenzidine (DAB)- and horseradish peroxidase 
(HRP)–based assay. The new HQ-tyramide IHC detection sys-
tem proved to be very useful for detecting low levels of ALK 
protein expression in NSCLC.
We also developed a brightfield IHC–in situ hybrid-
ization (ISH) combination assay (gene–protein assay) for 
the concurrent visualization of ALK protein and ALK gene 
arrangement. To make the IHC portion of this combination 
assay compatible with ISH, we incorporated another novel, 
nonendogenous hapten [5-nitro-3-pyrazole (NP)] and a novel 
chromogen (fast gold) into a new alkaline phosphatase (AP)–
based assay. Combined with break-apart ISH methodology, 
this assay allows covisualization of ALK protein expression 
and ALK gene rearrangement.
MATERIALS AND METHODS
Reagents and Antibodies
All antibodies and IHC reagents were from Ventana 
Medical Systems, Inc. (Tucson, AZ; “Ventana”) and all 
chemical reagents were from Sigma (St. Louis, MO) unless 
stated otherwise. Polyethylene glycol (PEG) linkers were pur-
chased from Quanta Biodesign Ltd. (Powell, OH). Polyclonal 
goat anti-rabbit antibodies, HRP, and AP were obtained from 
Roche Diagnostics (Mannheim, Germany).
NSCLC and Xenograft Specimens
Eighty surgically resected, deidentified NSCLC cases 
(40 ALK-negative and 40 ALK-positive FISH) were provided 
by the National Cancer Center Hospital (Tokyo, Japan) after 
the study protocol was approved by the National Cancer 
Center Hospital Institutional Review Board. The specimens 
were fixed in 10% buffered formalin for 24 to 72 hours at room 
temperature, cut into serial, 5-mm–thick slices, and examined 
by eye for the presence of tumor and surrounding lung tissue. 
The specimens were then routinely processed for embedding 
in paraffin. Sections of the paraffinized tissue were cut at 4-µm 
thickness and mounted on Matsunami Platinum glass slides 
(Matsunami Glass Ind., Ltd., Osaka, Japan). Hematoxylin and 
eosin slides from each specimen were examined to confirm 
the presence of NSCLC tumor.
The ALK gene status of NSCLC cases was examined 
using the Food and Drug Administration (FDA)–approved 
Vysis ALK Break Apart FISH Probe Kit assay (Abbott 
Molecular Inc., Des Plaines, IL; hereafter, Vysis ALK FISH 
assay). For this purpose, 50 nonoverlapping tumor cells from 
each case were analyzed, and those cases exhibiting split-apart 
or lone 3′ signals in at least 15% of tumor cells were consid-
ered to be positive for ALK rearrangement (Table 1).
Randomly selected ALK-negative and -positive NSCLC 
cases were used to prepare two tissue microarray (TMA) 
blocks for assay optimization. One TMA block was prepared 
with ALK-positive NSCLC cases (14 tissue cores) whereas the 
other TMA block was prepared with ALK-negative cases (16 
tissue cores). TMA slides and single-specimen–containing 
slides were then used in the ALK method development and 
assay performance studies, respectively, described herein.
The ALK-positive NCI-H2228 cell line (adenocarci-
noma, NSCLC cells) and the ALK-negative A549 cell line 
(adenocarcinoma, human alveolar basal epithelial cancer 
cells) were used to produce FFPE xenograft tumors. Both 
xenograft tumors were embedded together in the same paraf-
fin block. Xenograft tumor sections were used for ALK gene–
protein assay development.
ALK IHC Methods
Three HRP-based IHC-detection methods (detections 
1–3; Fig. 1A) and two AP-based IHC-detection methods (detec-
tions 4 and 5; Fig. 4A) were investigated for their ability to 
detect low-level ALK protein expression using ALK-positive 
and -negative NSCLC TMA sections. IHC staining was per-
formed on a VENTANA BenchMark XT automated slide-pro-
cessing system (Ventana), using Vysis ALK FISH-characterized 
NSCLC tissue sections. For all IHC staining, the BenchMark 
XT instrument heated the slides carrying the FFPE tissue sec-
tions at 65°C for 20 minutes to improve tissue adhesion and 
then performed the following steps: (1) deparaffinization with 
EZ Prep detergent solution (Ventana) (75°C; 20 minutes); (2) 
washing with reaction buffer; (3) ALK antigen retrieval in Cell 
Conditioning 1 (Ventana) (100°C; 92 minutes); (4) washing 
(same as step 2); (5) primary antibody (Ab) incubation with 
rabbit monoclonal anti-ALK Ab (clone D5F3; 36°C; 16 min-
utes); and (6) washing (same as step 2). All reagents used in 
these steps were from Ventana. All subsequent reagent incuba-
tion steps were separated by washing as in step 2.
In all three HRP-based IHC staining methods (detec-
tions 1–3), primary Ab incubation and washing were followed 
by secondary Ab incubation with a goat polyclonal anti-rabbit 
Ab. In detection 1, the secondary Ab was biotinylated, sub-
sequently bound by a streptavidin-HRP complex, and visu-
alized by means of a a brown precipitate produced by HRP 
on the addition of hydrogen peroxide and DAB. This DAB 
color reaction was also used in detections 2 and 3. However, 
in detection 2, the secondary Ab was conjugated to HQ 
rather than biotin, and HRP-conjugated mouse monoclonal 
anti-HQ Ab was used as a tertiary Ab to amplify the signal 
before the DAB color reaction was carried out. In detection 
3, the signal was amplified even further by the addition of an 
HQ-tyramide complex and a second layer of HRP-conjugated 
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mouse monoclonal anti-HQ Ab between the tertiary Ab and 
chromogenic reaction steps. In all three methods, the stained 
tissue sections were counterstained with modified Mayer’s 
hematoxylin (Hematoxylin II; Ventana) and then incubated 
with Bluing Reagent (Ventana) to change the hematoxylin hue 
to blue. They were then dehydrated through a graded ethanol 
series, cleared with xylene, and cover-slipped with Tissue-Tek 
Film Coverslipper (Sakura Finetek Japan, Tokyo, Japan).
In the two AP-based IHC methods (detections 4 and 
5), the goat polyclonal anti-rabbit secondary Ab was conju-
gated to NP, and the tertiary Ab was an AP-conjugated mouse 
monoclonal anti-NP Ab. Detections 4 and 5 differed in that 
the former used fast red and naphthol phosphate, a commonly 
used AP substrate, and the latter used fast blue BB and fast 
gold, a newly developed AP substrate. After counterstaining 
and bluing as described above, the slides were air-dried in a 
TABLE 1. ALK FISH Results of NSCLC Cases
Case Number
ALK FISH Result
Case Number
ALK FISH Result
ALK Status % Splita ALK Status % Splita
02 Positive 42 01 Negative 6
06 Positive 27 03 Negative 9
11 Positive 72 04 Negative 5
13 Positive 36 05 Negative 6
15 Positive 48 07 Negative 4
17 Positive 36 08 Negative 6
20 Positive 44 09 Negative 2
22 Positive 53 10 Negative 2
24 Positive 32 12 Negative 2
27 Positive 44 14 Negative 2
28 Positive 56 16 Negative 6
30 Positive 50 18 Negative 6
32 Positive 48 19 Negative 3
34 Positive 40 21 Negative 2
39 Positive 35 23 Negative 10
41 Positive 72 25 Negative 10
42 Positive 56 26 Negative 10
43 Positive 76 29 Negative 5
44 Positive 40 31 Negative 4
46 Positive 46 33 Negative 3
48 Positive 52 35 Negative 5
53 Positive 64 36 Negative 7
54 Positive 16 37 Negative 2
57 Positive 54 38 Negative 3
58 Positive 40 40 Negative 5
59 Positive 50 45 Negative 0
60 Positive 52 47 Negative 0
61 Positive 28 49 Negative 7
62 Positive 30 50 Negative 3
65 Positive 58 51 Negative 4
66 Positive 46 52 Negative 3
69 Positive 48 55 Negative 7
70 Positive 50 56 Negative 1
72 Positive 52 63 Negative 6
73 Positive 65 64 Negative 4
74 Positive 56 67 Negative 2
75 Positive 32 68 Negative 0
76 Positive 46 71 Negative 8
77 Positive 47 78 Negative 4
79 Positive 50 80 Negative 4
aPercentage of cells exhibiting split ALK gene signals or lone 3′ signals.
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; NSCLC, non–small-cell lung cancer.
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conventional oven (60°C; 20 minutes) and coverslipped with 
Tissue-Tek Film Coverslipper.
ALK IHC slides were scanned without magnification 
on an Epson Artisan 700 scanner (Epson America, Inc., Long 
Beach, CA) using Epson Scan software (Epson America, 
Inc.). Micrographs were captured using an ECLPE 90i micro-
scope (Nikon Instruments Inc., Melville, NY) equipped with 
a DS-Fi1 digital camera (Nikon Instruments Inc.). Captured 
images were prepared for figures using Adobe Photoshop CS5 
(Adobe Systems Inc., San Jose, CA).
ALK Gene–Protein Assay Application
For concurrent detection of ALK protein expression and 
ALK gene rearrangement in NSCLC and xenograft tissue sec-
tions, detection 5 was used in conjunction with a brightfield 
break-apart ISH assay (Fig. 5A). FFPE NSCLC tissue sections 
were mounted on Matsunami Platinum slides, baked (65°C; 
20 minutes), placed in the Benchmark XT instrument, and 
deparaffinized using EZ Prep as described above. They were 
then subjected to heat treatment in Cell Conditioning 1 for 92 
minutes for antigen retrieval. The slides were then incubated 
with rabbit monoclonal anti-ALK Ab (clone D5F3; 37°C; 16 
minutes), with NP-conjugated goat polyclonal antirabbit Ab 
(37°C; 8 minutes), and with AP-conjugated mouse monoclo-
nal anti-NP Ab (37°C; 8 minutes). ALK IHC staining was 
completed using the AP substrates fast gold and fast blue BB 
for 8 minutes.
Brightfield ALK break-apart ISH methodology12–14 was 
applied to ALK IHC slides with some modifications. For 
DNA target retrieval, the IHC-stained tissue sections were 
subjected to a second heat treatment in reaction buffer (90°C; 
48 minutes), digested with protease (ISH-Protease 3; Ventana) 
(37°C; 12 minutes), and denatured (80°C; 8 minutes). A cock-
tail of digoxigenin (DIG)-labeled 3′ ALK DNA probe and 
2,4-dinitrophenyl (DNP)-labeled 5′ ALK DNA probe was then 
hybridized to the tissue sections (44°C; 6 hours). Three strin-
gency washes (72°C; 3 × 8 minutes) were performed using 2× 
saline soldium citrate (SSC) (Ventana). For visualization of 3′ 
ALK probe-binding sites, the tissue sections were incubated 
sequentially with (1) mouse monoclonal anti-DIG Ab (37°C; 
20 minutes), (2) AP-conjugated goat polyclonal anti-mouse 
Ab for 20 minutes, and (3) naphthol and fast red, resulting 
in color development. The 5′ ALK probe-binding sites were 
visualized through sequential use of (1) rabbit monoclonal 
anti-DNP Ab (37°C; 20 minutes), (2) HRP-conjugated goat 
anti-rabbit Ab (20  minutes), and (3) modified HRP-Green (42 
Life Sciences GmbH & Co. KG, Bremerhaven, Germany; 
37°C; 16 minutes).
Stained tissue sections were lightly counterstained with 
diluted Mayer’s hematoxylin (1:5 in water; 42 Life Sciences), 
dried in a conventional oven (60°C; 20 minutes), and cov-
erslipped with a film coverslipper. Micrographs of the ALK 
gene–protein slides were captured as described above.
Preparation of Novel HQ and NP Reagents
First, the HQ and NP haptens (Ventana) were esteri-
fied with N-hydroxysuccinimide (NHS) by the following pro-
cedure: HQ- or NP-carboxylic acid (5.0 mmol, 1.0 eq) was 
taken up in anhydrous dichloromethane (DCM; 10 ml) in a 
50-ml round-bottom flask. The solution was blanketed with 
anhydrous nitrogen gas (N
2
), and NHS (5.5 mmol, 1.1 eq) was 
added followed by N,N′-dicyclohexylcarbodiimide (6.0 mmol, 
1.2 eq, 1.0 M in DCM) and triethylamine (6.0 mmol, 1.2 eq; 
TEA). The reaction mixture was stirred at room temperature 
(RT) under N
2
 for 16 hours, at which point the solvent was 
removed under vacuum. The residue was taken up in DCM 
(2 ml) and filtered to remove the urea byproduct. The resulting 
filter cake was washed twice with DCM (0.5 ml). The DCM 
washes were dried under vacuum to yield the HQ- or NP-NHS 
ester, which was used without further purification.
Next, the HQ and NP haptens were covalently linked 
to H
2
N-PEG-COOH by the following procedure: the hapten-
NHS ester (5.0 mmol, 1.0 eq) was taken up in DCM (10 ml) in 
a 50-ml round-bottom flask. The solution was blanketed with 
N
2
, and H
2
N-PEG-COOH (5.5 mmol, 1.1 eq) was added fol-
lowed by TEA (6.0 mmol, 1.2 eq). The reaction mixture was 
stirred at RT under N
2
 for 16 hours. The solvent was removed 
under vacuum. The residue was taken up in a minimum vol-
ume of methanol and purified by preparative HPLC. The 
appropriate fractions were then pooled and dried under high 
vacuum to give the pure NP- or HQ-PEG-COOH.
Finally, to make the HQ- and NP-PEG-NHS ester 
reagents, HQ- or NP-PEG-COOH (5.0 mmol, 1.0 eq) was 
taken up in DCM (10 ml) in a 50-ml round-bottom flask. The 
solution was blanketed with N
2
, and NHS (5.5 mmol, 1.1 
eq) was added, followed by N,N′-dicyclohexylcarbodiimide 
(6.0 mmol, 1.2 eq, 1.0 M in DCM), and TEA (6.0 mmol, 1.2 
eq). The reaction mixture was stirred at RT under N
2
 for 16 
hours. The solvent was removed under vacuum, and the resi-
due was taken up in DCM (2 ml) and filtered to remove the 
urea byproduct. The resulting filter cake was then washed 
twice with DCM (0.5 ml). The combined DCM washes were 
then dried under vacuum to yield the hapten-PEG-NHS ester, 
which was used without further purification.
Preparation of NP- and HQ-Conjugated  
PEG-Tyramides
To make HQ- and NP-conjugated PEG-tyramides, the 
HQ- or NP-PEG-NHS ester (5.0 mmol, 1.0 eq) was taken up 
in DCM (10 ml) in a 50-ml round-bottom flask. The solution 
was blanketed with N
2
, and tyramine (7.5 mmol, 1.5 eq) was 
added followed by TEA (10.0 mmol, 2.0 eq). The reaction 
mixture was stirred at RT under N
2
 for 16 hours. The solvent 
was removed under vacuum, and the residue was taken up 
in a minimal volume of methanol or DCM and purified by 
either preparative HPLC or automated flash chromatography. 
The appropriate fractions were pooled and dried under high 
vacuum to yield pure NP- or HQ-PEG-tyramide. The recovery 
typically ranged between 70% and 85%.
Preparation of NP- and HQ-Conjugated  
Goat Abs
To prepare the hapten-conjugated goat anti-rabbit Abs, 
polyclonal goat Ab in phosphate-buffered saline (pH 7.0–7.5) 
was treated with a solution of HQ- or NP-PEG-NHS (20 eq) 
in anhydrous DMSO at a final DMSO concentration less than 
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10% (vol/vol). Reaction mixtures were incubated for 18 hours 
in an amber vial at room temperature with rotation, passed 
through a 0.2-μm GHP syringe filter, and loaded onto a size 
exclusion chromatography column (Superdex 200 10/300 GL; 
GE Healthcare Life Sciences, Piscataway, NJ) connected to an 
AKTA Purifier running phosphate-buffered saline, pH 7.2, at 
0.9 ml/minute. Typical yields were 70% to 80%, with 4 to 6 
haptens bound per Ab.
Preparation of HRP-Conjugated Abs
To activate HRP, maleimide-PEG-NHS ester 
(α-maleimide-ω-NHS ester PEG; 78.8 mg, 100 eq) was 
mixed with 2.46 ml of HRP (61.5 mg, 1.53 μM) as a 25 mg/ml 
solution in 0.1 M sodium phosphate, pH 7.5. The vial was 
placed on an autorotator in the dark at ambient temperature 
(23–25°C), and the amide bond-forming reaction was allowed 
to proceed for 1 hour. A 400-μl aliquot was removed for puri-
fication, and the remainder of the solution was stored at 4°C. 
Pure HRP-PEG-maleimide was obtained by fractionation on a 
Superdex 200 10/300 column connected to an AKTA Purifier 
running 0.1 M sodium phosphate, pH 7.5, at 1.0 ml/minute. 
Pooling of the HRP-containing fractions yielded 2.0 ml of a 
4.5 mg/ml solution of HRP-PEG-maleimide (90% recovery) 
as measured by ultraviolet/visible (UV/vis) spectrophotom-
etry using an absorbance value at 280 nm (A
280
) of 6.52 for a 
1% solution (pH 6.5).
To activate the mouse anti-hapten (NP or HQ) monoclo-
nal Abs for conjugation, each Ab (2.1 mg/ml in 0.1 M sodium 
phosphate, 1.0 mM ethylenediaminetetraacetic acid [EDTA], 
pH 6.5) was mixed with 216 μl of a freshly prepared 500 mM 
solution of 1,4-dithiothreitol (DTT). The vial was placed in 
the dark on an autorotator, and the disulfide reduction was 
allowed to proceed for 25 minutes. For removal of excess 
DTT, the reaction solution was then divided into four equal 
batches (because of the limited capacity of the desalting col-
umn), and each batch was passed through a PD-10 desalting 
column and was eluted with 0.1 M sodium phosphate, 1.0 mM 
EDTA, pH 6.5. The Ab-containing fractions were combined 
to yield 8.0 ml of a 0.8 mg/ml solution of reduced mouse anti-
hapten (NP or HQ) Ab, as determined by UV/vis spectropho-
tometry using an A
280
 of 1.4 for a 1% solution.
To conjugate HRP to the anti-hapten Ab, the reduced Ab 
was added to a threefold molar excess of HRP-PEG-maleimide 
and incubated at ambient temperature (23–25°C) for 16 hours. 
The reaction mixture was passed through a Superdex 200 
10/300 GL SE column to remove the unbound HRP. As deter-
mined by calculating A
280
:A
403
, an average of two or three HRP 
molecules were covalently bound to each Ab molecule. The 
HRP-Ab conjugates were stored at 4°C until use.
Preparation of AP-Conjugated Abs
To activate AP for conjugation to the mouse anti-hapten 
(HQ or NP) monoclonal Abs, it was treated with a 100-fold 
molar excess of maleimide-PEG-NHS ester at ambient tem-
perature for 60 minutes. The maleimide-activated AP was 
then purified from the reaction mixture on a Superdex 200 
10/300 GL column equilibrated with AP buffer (0.1 M Tris-
HCl, 1 mM MgCl
2
, 0.1 mM ZnCl
2
, pH 7.5).
The mouse anti-hapten (HQ or NP) monoclonal Abs 
(2.1 mg/ml in 0.1 M sodium phosphate, 1.0 mM EDTA, pH 
6.5) were mixed with 216 μl of a freshly prepared solution of 
DTT (500 mM). The vials containing the disulfide reduction 
reaction mixtures were placed in the dark with rotation for 25 
minutes. The reaction mixtures were then split into four equal 
batches (because of the limited capacity of a desalting col-
umn used), and excess DTT was removed by batch-wise chro-
matography on a PD-10 desalting column eluted with 0.1 M 
sodium phosphate, 1.0 mM EDTA, pH 6.5. The Ab-containing 
fractions were combined to give 8.0 ml of a 0.8 mg/ml solution 
of purified, thiolated mouse anti-NP or -HQ Ab, as determined 
by UV/vis spectrophotometry.
To conjugate the activated AP to the thiolated Abs, 
the Abs were combined with a threefold molar excess of the 
maleimide-AP and incubated at ambient temperature for 16 to 
18 hours. The AP-conjugated Abs were purified on a Superdex 
200 10/300 GL column equilibrated with AP Buffer.
Preparation of Fast Gold AP Substrate
For fast gold synthesis, phosphoryl chloride (11.5 
mmol, 2.0 eq) was taken up in 5 ml of DCM in a 100-ml 
round-bottom flask fitted with an addition funnel and sep-
tum. The solution was blanketed with N
2
. In a separate vessel, 
3-methyl-1-phenyl-pyrazoline-5-one (5.7 mmol, 1.0 eq) and 
TEA (17.2 mmol, 3.0 eq) were dissolved in DCM (20 ml). 
The mixture was transferred to the addition funnel and added 
drop-wise to the reaction over a 1-hour period. Four hours 
after the final drop was added, the solvent was removed under 
vacuum, and the residue was dissolved in saturated aque-
ous ammonium carbonate (25 ml). After overnight stirring, 
the solution was washed with DCM, and the aqueous layer 
was concentrated under vacuum. The residue was taken up 
in a minimal volume of methanol and purified by preparative 
HPLC. The appropriate fractions were then pooled, frozen, 
and lyophilized to give the product 3-methyl-1-phenyl-
1H-pyrazol-5-yl phosphate, bis-triethylammonium salt as a 
white powder, with a yield of 20%.
ALK IHC Scoring Guideline and Statistical  
Analyses
For assay development and optimization of detections 
1 to 5 using ALK-positive and -negative NSCLC TMA slides, 
the intensity of ALK protein immunoreactivity in tumor cells 
was scored as 0, 1+, 2+, and 3+ by an investigator (H.N.). 
Because the sample size was small, no statistical analysis was 
applied to the optimization results.
To further evaluate the performance of detection 3, three 
blinded pathologists (K.T., A.Y, S.N.H.) scored 80 random-
ized NSCLC cases (whole-tissue sections) for ALK diag-
nostic status, using the H-score method.15 In this method, the 
percentages of cells with various IHC staining intensities (0, 
1+, 2+, or 3+) are quantified so that they sum up to 100%. The 
H-score is then calculated as follows:
H-score =  percentage of 1+ cells + (2 × percentage of 2+ cells) 
+ (3 × percentage of 3+ cells).
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FIGURE 1.  Three DAB-based methods for IHC detection of ALK protein. A, Schematic diagrams of detections 1, 2, and 3. In all 
three methods, the target is localized through the HRP-catalyzed deposition of DAB. Detection 1 is a conventional DAB method 
in which the binding of a biotin-conjugated secondary antibody (black) to the target-bound primary antibody (red) is detected 
using a streptavidin-HRP complex (green) that binds to the biotin (purple). In detection 2, the IHC signal is amplified through 
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H-scores can range from 0 to 300. The ALK IHC 
H-scores for all three readers were compared with the FISH 
results for each case. The H-score cutoff for ALK positivity 
was adjusted to maximize the overall agreement between the 
FISH and IHC results. This cutoff (H-score = 50) was then used 
to calculate the overall agreement between each reader’s IHC 
and FISH results. Agreement rates for ALK status among read-
ers were also calculated. The data were recorded in Microsoft 
Excel Spreadsheets, and SAS 9.2 was used for data analysis.
RESULTS
Sensitivity of Three DAB-Based ALK  
IHC-Detection Methods
To develop a highly sensitive assay for detection of 
ALK expression in NSCLC tissues, we first examined three 
DAB-based IHC-detection systems (Fig. 1A). The slides used 
in this analysis contained TMAs of FFPE NSCLC specimens 
that had been found to be positive or negative for ALK gene 
rearrangement using the Vysis ALK FISH assay (14 and 16 
tissue cores, respectively).
We used a conventional DAB-based method (detection 
1) as a baseline for comparison. In this method, a biotinylated 
goat antirabbit secondary Ab is bound by a streptavidin-HRP 
complex. Because tyramide amplification is used to increase 
IHC assay sensitivity, we next considered improving the 
detection method by including a tyramide signal amplification 
system. However, a well-recognized problem in biotinylated 
tyramide signal amplification is an increase in background 
staining caused by the presence of endogenous biotin-like 
molecules.16 Therefore, in detection 2, we replaced the biotin 
in our IHC system with a nonendogenous hapten (HQ). The 
FIGURE 2.  Distribution of ALK IHC 
H-scores in NSCLC cases previously 
found to be ALK-negative (A) or 
ALK-positive (B) by the Vysis FISH 
assay. Cases with an H-score of 50 
or greater were classified as ALK 
positive. Ninety percent of the ALK-
negative cases had an H-score of 0. 
ALK, anaplastic lymphoma kinase; 
IHC, immunohistochemistry; NSCLC, 
non–small-cell lung cancer.
FIGURE 1. (Continued)  the use of a tertiary antibody. The secondary antibody is conjugated to the hapten 3-hydroxy-2-qui-
noxaline (HQ; blue) rather than biotin, and the anti-HQ tertiary antibody is conjugated to HRP (green). In detection 3, the sig-
nal is further amplified using an HQ-conjugated tyramide bridge (gray). B, Images of ALK-negative (upper row) and ALK-positive 
(lower row) NSCLC cases stained using the three IHC methods (×20) on the same region of the same sample. The ALK-negative 
tissue exhibits no positive staining with any of the three detection systems. The ALK IHC staining signal in the ALK-positive 
samples increases substantially from detection 1 to detection 2 and from detection 2 to detection 3, without a concomitant 
increase in background staining. ALK, anaplastic lymphoma kinase; DAB, diaminobenzidine; HRP, horseradish peroxidase; IHC, 
immunohistochemistry; NSCLC, non–small-cell lung cancer.
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HQ was used to amplify the ALK signal without tyramide by 
attaching it to the goat anti-rabbit secondary Ab and adding 
an HRP-conjugated anti-HQ Ab. In detection 3, we added the 
tyramide amplification system to detection 2.
When we compared the ALK protein-detection sensitiv-
ity of the two amplified, DAB-based IHC methods (detections 
2 and 3) with that of detection 1, a clear difference emerged 
(Fig. 1B). All three detection systems yielded negative stain-
ing (IHC intensity score of 0 or <1+) on all 16 NSCLC tis-
sue cores identified as ALK negative by the Vysis ALK FISH 
assay. However, of the 14 cores found to be ALK positive by 
the Vysis ALK FISH assay, detection 1 yielded negative results 
for four cores, whereas detections 2 and 3 yielded positive 
results for 14 cores. Furthermore, whereas detection 2 yielded 
3+, 2+, and 1+ staining intensities for 6, 3, and 5 of the ALK 
FISH–positive cores, respectively, detection 3 yielded them 
for 12, 2, and 0 of the ALK FISH–positive cores, respectively. 
Thus, detection 3 demonstrated the best sensitivity for detect-
ing ALK protein in FFPE NSCLC tissue cores. Furthermore, 
we observed ALK IHC–negative tumor cells within the whole 
sections of ALK FISH–positive NSCLC cases with detection 
2 (data not shown).
Performance Evaluation of the HQ-Tyramide  
IHC Detection Method
We evaluated the HQ-tyramide IHC detection sys-
tem (detection 3) by applying it to whole sections of the 40 
ALK FISH–positive and 40 ALK FISH–negative NSCLC 
cases (Table 1) and having three independent, board-certified 
FIGURE 3.  Visualization of ALK expression in 
NSCLC cases using a tyramide-amplified DAB IHC 
method (detection 3). A, Representative nonmagni-
fied images of detection 3–stained NSCLC sections 
reveal an absence of staining in an ALK-negative 
tumor (left), and homogenous (middle) or hetero-
geneous (right) staining in two different ALK-positive 
tumors. The homogenous- or heterogeneous-type 
staining pattern is present throughout the malignant 
tissue. B, Images of detection 3–stained NSCLC sec-
tions through a ×60 objective lens. The ALK-negative 
NSCLC cases showed no ALK IHC signal (left). 
ALK-positive NSCLC tissues exhibit homogeneous 
(middle) or heterogeneous (right) ALK IHC stain-
ing. Malignant cells failing to demonstrate ALK IHC 
staining within an ALK-positive tumor were rarely 
observed. ALK, anaplastic lymphoma kinase; DAB, 
diaminobenzidine; IHC, immunohistochemistry; 
NSCLC, non–small-cell lung cancer.
TABLE 2.  Agreement Between ALK Status Results for IHC 
Versus FISH Assays by Reader
Reader ALK IHCa
ALK FISH
Positive Negative Total
Reader 1 Positive 40 0 40
Negative 0 40 40
Total 40 40 80
Reader 2 Positive 40 1 41
Negative 0 39 39
Total 40 40 80
Reader 3 Positive 40 0 40
Negative 0 40 40
Total 40 40 80
aALK IHC detection 3 method.
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FIGURE 4.  Comparison of a tyramide-amplified DAB IHC ALK-detection method (detection 3) with two AP-based IHC ALK-
detection methods (detections 4 and 5). A, Schematic comparison of the IHC methods. Detection 3, which uses HQ-conjugated, 
tyramide-amplified IHC detection with HRP-catalyzed deposition of DAB, was used as a control for assay sensitivity. Detections 4 
and 5 both use a 5-nitro-3-pyrazole (NP)-conjugated secondary antibody and an AP-conjugated anti-NP antibody. For target visual-
ization, detection 4 uses fast red, whereas detection 5 uses fast gold. B, Performance of tyramide-amplified DAB (detection 3; left)  
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pathologists familiar with ALK IHC staining evaluate the 
resulting slides. The slides were randomized and blinded 
for FISH status before ALK IHC scoring. The pathologists 
scored the slides using the semiquantitative H-score method15 
described in Materials and Methods section. A threshold 
H-score value of 50 was selected to maximize the concor-
dance between the results of the Vysis ALK FISH assay and 
the detection 3 IHC assay; cases with an H-score of 50 or 
greater were classified as ALK IHC positive, and cases with 
an H-score of less than 50 were classified as ALK IHC nega-
tive (Fig. 2).
The readers assigned H-scores of zero for 90% of the 
ALK FISH–negative cases. The IHC interpretations of read-
ers 1 and 3 agreed with the FISH results 100% of the time 
(score 95% confidence interval, 95.4%–100.0%), whereas 
interpretations of reader 2 disagreed with the FISH results for 
one case (98.8% concordance; score 95% confidence interval, 
93.3–99.8%; Table 2). All interreader agreement rates were 
greater than 98%. Only one case was discordant (FISH nega-
tive and IHC positive), with an H-score of 70 by one observer.
Differentiated ALK Protein Staining Patterns  
in NSCLC Visualized by HQ-Tyramide IHC  
Detection
The ALK IHC status of almost all of the surgical 
NSCLC cases was visually determinable by the naked eye, but 
both homogeneous and heterogeneous macroscopic patterns 
of ALK protein expression were observed (Fig. 3A). Twelve 
ALK IHC–positive cases showed homogeneous macroscopic 
patterns of ALK staining and 27 ALK IHC–positive cases 
showed heterogeneous ALK staining. The ALK positivity 
of one case with weak ALK IHC staining was obvious only 
under a microscope. Under brightfield microscopic examina-
tion, nearly all of the ALK IHC–positive tumor cells exhibited 
positive staining for ALK protein in those cells morphologi-
cally classified as malignant (Fig. 3B).
Development of the ALK Gene–Protein Assay
In developing a dual IHC-ISH brightfield assay for ALK 
diagnostic status, we found that combining the DAB-based, 
HQ-tyramide–amplified IHC system (detection 3) with a 
brightfield break-apart ISH assay yielded unacceptably dark 
cytoplasmic DAB staining that obscured the ISH signal (data 
not shown). Therefore, we sought to develop an alternative 
IHC detection system for colocalizing ALK protein expression 
and ALK gene rearrangement. Two AP-based systems using 
the novel hapten NP were developed; as chromogens, detec-
tion 4 used fast red, a commonly used AP chromogen, whereas 
 detection 5 used fast gold, a newly developed AP chromogen.
When we compared the tyramide-amplified, DAB-based 
IHC assay system (detection 3) and the NP-incorporated 
AP-based systems (detections 4 and 5; Fig. 4A), both of the 
NP systems demonstrated outstanding sensitivity similar 
to that observed for the tyramide-based DAB IHC system 
and superior staining resolution and dynamic range on ALK 
FISH–positive TMA slides (Fig. 4B). The sensitivity and 
specificity of detections 4 and 5 were very similar; both detec-
tion systems stained ALK FISH–positive cases at equivalent 
and unambiguously positive levels of intensity (2+ or 3+) 
and yielded no significant staining of tumor cells in any ALK 
FISH–negative cases on TMA slides (Fig. 4B).
When we optimized the ALK gene–protein assay using 
xenograft tumors with known ALK status, we found that the 
optimal procedure combined detection 5 with a subsequent 
break-apart ALK ISH assay (Fig. 5A). The optimized proce-
dure produces a gold signal for ALK protein and green and 
red signals for the 5′ and 3′ ALK gene regions, respectively, 
in ALK-positive NSCLC cases. In ALK-negative xenograft 
tumor tissue sections, the proximity of the non–split-apart 5′ 
and 3′ ALK regions superimposed the green and red signals, 
forming dark brown/black signals, whereas in ALK-positive 
xenograft tumor sections, discrete green and red signals were 
visible wherever the 5′ and 3′ ALK regions were split apart, in 
addition to superimposed green and red ISH signals (Fig. 5B). 
When used on ALK-negative NSCLC tumors, the assay exhib-
ited no immunoreactivity for ALK protein, and the majority 
of tumor cells showed fused 5′ and 3′ ALK ISH signals (Fig. 
5C, left). When the assay was used on ALK-positive NSCLC 
tumors, both homogeneous staining (consistent ALK immu-
nostaining throughout the tumor area; Fig. 5C, top middle) 
and heterogeneous staining (uneven ALK immunostaining 
within the tumor area; Fig. 5C, top right) were observed, but 
both staining patterns also demonstrated discrete 5′ and 3′ 
ALK ISH signals in the majority of tumor cells (Fig. 5C, bot-
tom middle and right).
DISCUSSION
The most common type of patient specimen used in the 
clinical diagnostic analysis of patient biomarker status, as 
well as in basic and medical biomarker research, is the FFPE 
tissue specimen.17,18 The clinical analysis typically involves 
well-established assay methodologies involving IHC, ISH, 
or PCR.
Crizotinib was FDA-approved for treatment of ALK-
positive NSCLC patients in 2011, only 4 years after the 
discovery of ALK gene rearrangement in NSCLC3 and the elu-
cidation of the mechanism by which the rearrangement leads 
to tumor development.19 The only FDA-approved ALK status 
testing method is the Vysis ALK FISH assay, which is used 
as companion diagnostic test for identifying patients likely 
to respond to crizotinib treatment. This test offers two major 
advantages: it can detect all variants of ALK gene rearrange-
ment, and each FISH slide contains an internal control for the 
FIGURE 4. (Continued)  and AP-based (detections 4 and 5; center and right) ALK IHC methods. None of the methods caused 
detectable background staining in an ALK-negative NSCLC tissue section (top). Relative to tyramide-amplified DAB, AP-based fast 
red IHC stained ALK-positive NSCLC tissue with similar sensitivity but with a wider dynamic range and better resolution (middle). 
AP-based fast gold IHC staining (right) was similar to AP-based fast red IHC staining (middle) in sensitivity (objective lens, ×20). 
ALK, anaplastic lymphoma kinase; AP, alkaline phosphatase; DAB, diaminobenzidine; HRP, horseradish peroxidase; HQ, 3-hydroxy-
2-quinoxaline; ssIHC, immunohistochemistry; NSCLC, non–small-cell lung cancer.
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assay performance (fused FISH signals in nontumor cells). 
However, its utility is limited by the instability of and complex 
patterns created by FISH signals, by the need for test interpre-
tation training, and its use of fluorescent probe tags requiring 
specialized equipment for visualization (i.e., a fluorescence 
microscope). Furthermore, fluorescence visualization com-
promises the effective recognition of tissue  morphology. 
Therefore, the implementation of ALK FISH testing by any 
clinical laboratory is not an easy task.
Meanwhile, IHC testing for expression of ALK protein 
in FFPE NSCLC tissue sections20–26 offers the major advan-
tage that the procedure is relatively simple. However, the low 
level of ALK protein expressed in ALK-positive NSCLC tis-
sue means that the sensitivity and specificity of ALK IHC 
assay must be carefully optimized for pretreatment method, 
Ab clone,20,21,26 and IHC detection system.20,23 Therefore, the 
key to successful implementation of the IHC ALK assay as a 
companion diagnostic test is standardization. Unfortunately, 
FIGURE 5.  Simultaneous detection of ALK protein 
expression and ALK gene rearrangement using the 
ALK gene–protein assay. A, Schematic diagram of 
the assay. First, ALK protein is stained using detec-
tion 5, an IHC method using an NP-conjugated 
secondary antibody, an AP-conjugated tertiary 
antibody, and the chromogen fast gold (top). Next, 
the IHC-stained tissue sections are cohybridized 
with ALK break-apart probes. Binding of the 3′ ALK 
probe is visualized using AP-based ISH with the 
chromogen fast red (middle). Finally, binding of the 
5′ ALK probe is visualized using HRP-based ISH with 
the chromogen HRP-green (bottom). B, ALK gene–
protein assay staining of xenograft tumors produced 
from the lung cancer cell lines A549 (ALK negative; 
left) and NCI-H2228 (ALK positive; right). In both 
tumors, wild-type (nonsplit) gene copies appear as 
dark dots of superimposed red and green signals. 
In the ALK-positive tumor, ALK protein expression is 
localized by gold staining, and split-apart 5′ and 3′ 
ALK regions appear as discrete green and red dots, 
respectively. No gold ALK protein signal is visible 
in the ALK-negative tumor (objective lens, ×100). 
C, ALK gene–protein assay staining of NSCLC cases 
shown with objective lens at ×20 (top) and ×100 
(bottom). The gold ALK protein IHC signal is absent 
in ALK-negative cases (left) whereas it is clearly vis-
ible in both the homogeneous and heterogeneous 
ALK-positive cases (center and right, respectively). 
The ISH signals in the ALK-negative NSCLC case 
(bottom left) appear only as superimposed red and 
green dots, whereas they often appear as discrete 
green and red dots in both types of ALK-positive 
cases. ALK, anaplastic lymphoma kinase; AP, alkaline 
phosphatase; HRP, horseradish peroxidase; IHC, 
immunohistochemistry; ISH, in situ hybridization; 
NP, 5-nitro-3-pyrazole; NSCLC, non–small-cell lung 
cancer.
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because normal lung tissues do not express ALK protein at 
detectable levels, ALK IHC methods lack internal controls, 
and thus may require control tissues in clinical use. Given the 
relative advantages and disadvantages of current ALK IHC 
and ALK FISH assays, testing of both types might be required 
for accurate ALK status evaluation of NSCLC patients. In fact, 
a recent report described a case in which an NSCLC patient 
specimen tested negative for ALK gene rearrangement by 
FISH but positive for ALK expression by IHC; the patient was 
effectively treated with crizotinib.8
Multiplex RT-PCR methodologies can rapidly and accu-
rately detect known variants of ALK fusion genes7,9 in sputum, 
bronchial lavage fluid, and pleural effusion samples,10 and are 
more sensitive and less subjective than ALK IHC and ALK 
FISH methodologies.7 However, multiplex RT-PCR is not rec-
ommended for clinical use for the detection of ALK gene rear-
rangement in FFPE samples,6,10 largely because it is difficult to 
extract high-quality RNA from FFPE tissue sections. In fact, 
clinical use of a quantitative RT-PCR assay for HER2 testing 
of FFPE samples raised concern27 because it yielded unaccept-
ably high false-negative rates (relative to the HER2 IHC and 
HER2 FISH methods) in an independent study.28 Furthermore, 
RT-PCR–based methods cannot detect as-yet-uncharacterized 
ALK fusion gene variants and do not allow the assessment of 
biomarker status in the context of tissue morphology.
In our endeavors to develop improved testing method-
ologies for determining ALK clinical status, we first developed 
a sensitive HQ-tyramide IHC assay that reproducibly stained 
ALK protein in FFPE NSCLC tissue sections with low back-
ground, revealing both homogeneous and heterogeneous macro-
scopic patterns of ALK protein expression. Although surgically 
resected tumors sometimes exhibit immunostaining gradients 
associated with fixation gradients, the heterogeneity observed 
for the ALK staining pattern did not seem to be a consequence 
of fixation heterogeneity. Whereas fixation gradients result 
from the time required for complete penetration of fixative into 
a sample and appear as a variation in immunostaining intensity 
(growing either darker or lighter, depending on the biomarker 
and detection system) from the center of the sample to its 
periphery,29 the heterogeneity observed in our specimens did not 
present in a typical gradient pattern (Fig. 3A), instead appearing 
intermingled (Fig. 3B). Under brightfield microscopic examina-
tion, nearly all of the ALK-positive samples exhibited positive 
staining for ALK protein in those cells morphologically clas-
sified as malignant. Thus, the heterogeneity seemed to reflect 
actual variations in the level of ALK fusion gene expression in 
the tumor. Stability differences among various ALK fusion gene 
products30 might also be a factor in heterogeneous ALK protein 
staining. Heterogeneity in ALK protein expression or stability 
could be a confounding factor in slide-based ALK testing, as 
a small biopsy sample taken from the wrong area of a hetero-
geneous ALK-positive tumor might not contain enough ALK-
positive cells to call positive.
Concurrent or simultaneous assessment of ALK protein 
expression and ALK gene rearrangement in the same tissue 
section is currently the most promising approach for devel-
oping an improved ALK clinical test. However, our initial 
attempts to combine our HQ-tyramide–amplified IHC method 
with brightfield break-apart ISH were not successful when 
one of the ISH probes was labeled with DNP (a frequently 
used hapten) and DAB was used for IHC detection (data were 
not shown). An undesired interaction between DAB and DNP 
produced high background staining. Also, dark cytoplasmic 
DAB staining of ALK IHC obscured the nuclear ISH signals. 
Therefore, we sought to develop an ISH-compatible IHC 
detection system with translucent staining.
We first developed a non–DAB-based, non-tyramide-
amplified IHC detection system incorporating AP, NP, and 
fast red (detection 4). Surprisingly, when compared with the 
HQ-tyramide DAB IHC detection system (detection 3) in 
FFPE NSCLC specimens on TMA slides, this system exhib-
ited similar ALK protein detection sensitivity, superior resolu-
tion, and a wider dynamic range. Because fast gold, a newly 
developed chromogen, produces translucent gold staining at 
AP sites when used with fast blue BB, we created a modified 
AP-NP IHC system incorporating fast blue BB and fast gold 
(detection 5). This detection system was similar in ALK sensi-
tivity to the fast red-based system. Fast gold IHC detection was 
combined with a chromogenic break-apart ALK ISH assay that 
produces red and green signals. The ISH procedure was per-
formed after the IHC procedure because we previously noted 
that the sensitivity and quality of protein detection in gene–
protein assays decreases when ISH is performed before IHC.31
When our ALK gene–protein assay was used on tumor 
sections of xenografts of the ALK-positive lung cancer cell 
line NCI-H2228, ALK protein expression appeared heteroge-
neous. Like the HQ-tyramide assay, it produced both homoge-
neous and heterogeneous staining in different ALK-positive 
NSCLC cases, suggesting that ALK protein expression might 
be regulated differentially within a single tumor cell popula-
tion, leading to heterogeneous expression, or that ALK pro-
tein stability might vary among ALK-positive NSCLC cases, 
resulting in the appearance of heterogeneous expression.
In summary, our explorations of IHC systems for 
detecting low-level ALK protein expression in NSCLC tis-
sue sections have led to the development of both an HRP-
based method using HQ and tyramide amplification and an 
AP-based method using NP hapten amplification. When com-
bined with a chromogenic break-apart ISH assay, the latter 
creates a brightfield gene– protein assay that allows covisual-
ization of ALK protein and ALK gene rearrangement in FFPE 
NSCLC tissue sections. This tool for simultaneously assess-
ing both ALK protein expression (IHC) and ALK gene rear-
rangement (ISH) in NSCLC will be valuable for research on 
the mechanisms driving ALK-dependent malignancies and as 
a model of new diagnostic approach for identifying patients 
who might benefit from ALK-targeted therapies. More gener-
ally, it also provides proof of concept for the development of 
new methodologies for the simultaneous assessment of gene 
structure and protein-expression status in a single cell.
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